Israeli researchers identify hidden mechanism driving rapid antibiotic resistance

Bacteria are learning to survive antibiotics faster than we thought, and researchers at Israel's Technion have just figured out how. A team led by Dr. Idan Yelin and Professor Roy Kishony discovered that bacteria can rapidly manufacture dozens of copies of specific genes—a kind of molecular photocopying—that allow them to withstand drugs designed to kill them. The mechanism is so efficient that it may be happening even during routine, short courses of treatment. The work, published in Nature Microbiology, doesn't change how doctors treat patients today, but it opens a path toward new drugs that could disable this survival strategy and restore the power of antibiotics we've relied on for decades.

The threat is real and urgent. Antibiotic resistance ranks among the gravest public health challenges of our time. The more bacteria encounter antibiotics, the more likely they are to evolve defenses. Infections that were once simple to cure can become nearly untreatable. What Yelin's team uncovered is a previously hidden mechanism at the heart of this arms race: bacteria don't just randomly mutate to resist drugs. Instead, they use a process called gene amplification to selectively multiply the genes that help them survive. It's not a slow process. It's rapid, targeted, and devastatingly effective.

The researchers developed a computational tool named AmpliFinder and used it to analyze more than 10,000 bacterial samples grown in laboratory conditions. They focused on two species: Escherichia coli and Acinetobacter baumannii, both capable of causing serious human infections. What they found was a form of amplification unlike anything previously well understood. The bacteria create a single DNA segment that bridges distant regions of their genome, a connection so unusual that it had been invisible to earlier detection methods. Through this bridge, bacteria can rapidly produce multiple copies of resistance genes, adapting to progressively higher doses of antibiotics far faster than conventional amplification mechanisms would predict.

In one experiment using the antibiotic chloramphenicol, the researchers watched bacteria amplify a DNA segment containing the mdfA gene, which not only boosted their existing resistance but allowed them to tolerate increasingly potent doses of the drug. The same mechanism appeared when the team tested other antibiotics: ampicillin, widely used for many infections, and trimethoprim, a standard treatment for urinary tract infections. This is not a quirk limited to one drug or one bacterial species. It is a general mechanism, Yelin emphasized, capable of attaching to many different genes and amplifying them in ways that promote survival. The process constitutes a form of accelerated evolution, compressing what might take generations into days or weeks.

One striking finding: the amplification may not be permanent. As long as bacteria are exposed to an antibiotic, they maintain the extra gene copies. Remove the drug, and the bacteria reduce the number of copies and return to a more vulnerable state. This suggests a potential opening for intervention—a way to disrupt the mechanism and restore the bacteria's sensitivity to treatment. The researchers envision a future drug that could be given alongside an antibiotic, working in tandem to disable the gene-amplification process itself, much as antibiotics disable essential bacterial systems. Such a treatment might slow or prevent the rapid adaptation that makes infections so difficult to control.

But significant questions remain unanswered. The study was conducted on laboratory bacteria, not samples from hospitals or patients. While the two species examined are classified by the World Health Organization as high-priority superbugs, and while the mobile genetic elements that enable amplification exist in all bacterial types, the researchers cannot yet say how common this mechanism is among resistant bacteria actually infecting people. Yelin acknowledged that follow-up studies will need to measure its prevalence in real-world settings. The mobile genetic elements can pass between bacteria, suggesting that other infection-causing species may develop resistance through the same pathway, but that too remains to be confirmed.

The discovery does not change current clinical practice. Doctors will not alter antibiotic dosages or treatment duration based on this finding. There is no test yet to detect hidden resistance, no drug yet to inhibit the mechanism, no timeline for when either might exist. What the research does offer is direction—a new understanding of how bacteria outmaneuver our most powerful drugs, and a target for future intervention. In the years ahead, if researchers can translate this mechanism into a therapeutic strategy, they may be able to restore antibiotics to their former reliability. For now, the work stands as a reminder that bacteria are not passive victims of our drugs. They are adaptive, ingenious, and operating on a timescale that demands our urgent attention.